Hypotensive lipid-containing biodegradable intraocular implants and related methods

Abstract

Biocompatibie intraocular implants include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat or reduce a at least one symptom of an ocular condition, such as glaucoma.

1 - 48 . (canceled) 
     
     
         49 . A method of reducing intraocular pressure, the method comprising placing a biodegradable intraocular implant into the anterior chamber of an eye of a patient in need thereof, the implant comprising latanoprost or travoprost and a biodegradable polymer matrix that releases an amount of the latanoprost from the implant effective to reduce the intraocular pressure in the eye of the patient in need thereof, wherein the amount of the latanoprost is released into the eye for a period of time greater than about one week to less than about six months after the implant is placed into the anterior chamber of the eye. 
     
     
         50 . The method of  claim 49 , wherein the biodegradable polymer matrix comprises a polylactic acid polymer. 
     
     
         51 . The method of  claim 50 , wherein the biodegradable polymer matrix further comprises a polylactic acid polyglycolic acid copolymer. 
     
     
         52 . The method of  claim 49 , wherein the method is effective in maintaining the intraocular pressure in the eye at a reduced level. 
     
     
         53 . The method of  claim 49 , wherein the implant is injected into the anterior chamber of the patient with a needle. 
     
     
         54 . The method of  claim 52 , wherein the implant is injected into the anterior chamber of the patient with a needle.